eShopWorld Appoints Martim Avillez Oliveira as Chief Commercial Officer - EMEA and APAC
13.4.2021 09:01:00 EEST | Business Wire | Press release
eShopWorld (ESW), the leading cross-border ecommerce technology and services provider, today announces the appointment of Martim Avillez Oliveira as Chief Commercial Officer, EMEA and APAC.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210412005546/en/
eShopWorld appoints Martim Avillez Oliveira as Chief Commercial Officer - EMEA and APAC (Photo: Business Wire)
Oliveira is a former Executive Vice President at global supply chain and logistics specialist, Li & Fung, has 15 years of industry experience in retail and global sourcing, having worked with the world’s leading fashion brands and retailers, including Inditex, Marks & Spencer, J.Crew and Galeria Karstadt Kaufhof, managing end-to-end supply chains.
In his new role, Oliveira will drive forward ESW’s strategic growth and development with a focus on crafting routes to market within and between the EMEA and APAC that enable retailers and brands to meet the huge latent demand for direct-to-consumer (D2C) engagement in these territories. Oliveira previously served as a member of ESW’s Retail Advisory Council, providing strategic guidance and amplifying the company’s cross-border ecommerce proposition globally.
“2020 saw historic growth in year-on-year cross-border ecommerce sales and reinforced the importance of international ecommerce for the retail industry as an enabler to meet customer demand at its point of origin while mitigating against fluctuations in local markets,” said Tommy Kelly, CEO of ESW.
“ESW saw significant growth in demand from consumers in Asian countries, with the Philippines in particular being one of the fastest growing global markets last year for brands and retailers using our technology and services to sell internationally. Martim’s insights, expertise and relationships across both APAC and the EMEA will allow us to expand our reach in these territories, whose emerging middle class will be a significant driver of global demand for Western brands within a short period of time. As a member of the ESW Advisory Council, Martim has already had a significant role in realising our global expansion strategy in these markets and we are very excited to formally welcome him as part of our global leadership team during this time of unprecedented opportunity.”
During his time at Li & Fung, Oliveira, who lived in Hong Kong for 10 years, held full P&L responsibility for business units to excess of $800 million cost of goods and achieved a strong track record of generating year-on-year growth and revenue. He also coordinated the group business development activities in Europe and the US.
“The events of last year have clearly shown retail brands need to mitigate risks, diversify and balance their distribution to thrive. As home to eight of the world's ten largest megacities, Asia, which has a growing digitally native middle class in all countries who are brand and status hungry, offers enormous expansion opportunities for both established heritage and emerging disruptor brands,” commented Oliveira.
“But many of these brands don’t have the digital capabilities, local expertise or capital required to fully leverage international opportunities and, while it may be tempting to look toward marketplaces as a route to these markets, we know the highest value cross-border shoppers want to engage with and buy directly from brands. ESW offers a seamless end-to-end solution that helps brands capitalise on this golden era for direct-to-consumer, cross-border ecommerce.”
Oliveira concluded: “Having been at the forefront of design, product development, global sourcing and production management, ESW represents the next mile in the journey. It’s the upstream part of the chain, moving from physical to digital, focusing on getting goods to international markets, looking at the most cost-effective route and solutions, while delivering fully localised shopping experiences to consumers around the world.”
In addition to his role at ESW, Oliveira is also non-executive and an advisor to Tiger Chark, a New York based strategic Advisory firm, and a member of the board of the Portuguese - Hong Kong Chamber of Commerce and Industry.
Ends
Notes to Editors
About eShopWorld:
ESW is the cross-border ecommerce leader, empowering the world’s best-loved brands and retailers to make global shopping better, safer, simpler and faster, end-to-end. From compliance, data security, fraud protection, taxes, and tariffs to checkout, delivery, returns, customer service, and demand generation, our powerful combination of technology and human ingenuity covers the entire shopper journey across 200 markets.
Methodology:
ESW’s latest consumer survey was fielded from more than 22,000 consumers in 11 countries (Australia, Canada, Chile, France, Germany, Mexico, Russia, Singapore, Turkey, the UK and the US), who were surveyed online in December 2020. Gen Zers are defined as consumers ages 18–24, Millennials as ages 25–40, Gen Xers as ages 41–56, Baby Boomers as ages 57–75 and the Silent generation as ages 76–92. To gauge how Baby Boomers’ global online shopping preferences differ from those of Gen Zers and millennials (shoppers ages 40 and under), ESW looked specifically at survey responses from shoppers in seven countries: Australia, Canada, France, Germany, Russia, the UK and the US.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210412005546/en/
Contact information
For further press information, please contact Mecah at Fieldworks on:
mecah.omeara@fieldworksmarketing.co.uk
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
